VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Rotavirus Chimeric VP6 protein Vaccine
Vaccine Information
  • Vaccine Name: Rotavirus Chimeric VP6 protein Vaccine
  • Target Pathogen: Rotavirus
  • Target Disease: Gastroenteritis
  • Vaccine Ontology ID: VO_0004224
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Chimeric VP6 protein (Choi et al., 2002).
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0000351
    • Description: Adjumer
  • Immunization Route: intranasal immunization
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were lightly anaesthetized in a closed vessel with Metafane (methoxyflurane, Pitman–Moore Inc., Mundelein, IL). Vaccine formulations containing chimeric VP6 admixed with different adjuvants were then delivered intranasally or orally into groups of mice. Two i.n. doses (60 μl per dose, 30 μl per nostril) or two oral doses (100 μl per dose), separated by 2 weeks, were delivered. Each dose of immunogen consisted of 9 μg of purified chimeric VP6, which was mixed with LT(R192G) (10 μg), CTA1-DD (10 μg), Adjumer® (50 μg), CpG ODN (10 μg) or QS-21 (20 μg) just before immunization. The amounts of adjuvants used were based on the amounts determined for other immunogens. A group of unimmunized mice served as the control in each experiment (Choi et al., 2002).
  • Immune Response: Mice immunized with Adjumer®, CTA1-DD or LT(R192G), also developed low titers of fecal rotavirus IgA. Use of Adjumer as an adjuvant had a large IgG1 titer but no increase in IgG2a titer (Choi et al., 2002).
  • Challenge Protocol: Four weeks after the last immunization, mice were orally (gavage) challenged with 4×10^4 FFUs (100 μl, 100 SD50) of passage-9 EDIM rotavirus (Choi et al., 2002).
  • Efficacy: Mice immunized with chimeric VP6 and Adjumer had a 35% reduction in shedding of virus compared to unimmunized mice (Choi et al., 2002).
References
Choi et al., 2002: Choi AH, McNeal MM, Flint JA, Basu M, Lycke NY, Clements JD, Bean JA, Davis HL, McCluskie MJ, VanCott JL, Ward RL. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine. 2002; 20(13-14); 1733-1740. [PubMed: 11906760].